(Q33184837)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

title

Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

1 reference

1 reference

Martin J van den Bent

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

author name string

F E de Jongh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

R de Wit

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

J Verweij

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

A Sparreboom

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

G Stoter

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

M E L van der Burg

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

publication date

1 October 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

13 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

page(s)

2005-2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12376205%20AND%20SRC:MED&resulttype=core&format=json

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

13 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

High-dose cisplatin in hypertonic saline in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900242-3

7 January 2021